Bridge Bio

5 FDA decisions to watch in the fourth quarter
BioPharma Dive
Wed, 10/2/24 - 11:24 am
FDA
Bridge Bio
acoramidis
AstraZeneca
Daiichi Sankyo
Dato-DXd
Vertex Pharmaceuticals
Vanza Triple
PTC Therapeutics
Upstaza
Bristol Myers Squibb
Opdivo
BridgeBio presents detailed positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM)
Yahoo/GlobeNewswire
Sun, 08/27/23 - 04:28 pm
Bridge Bio
clinical trials
acoramidis
ATTR
ATTR-CM
10 clinical trials to watch in the second half of 2023
BioPharma Dive
Mon, 08/7/23 - 10:32 am
clinical trials
Sarepta Therapeutics
DMD
Elevidys
Bridge Bio
ATTR-CM
acoramidis
Sanofi
Merck KGaA
MS
tolebrutinib
Pfizer
obesity
danuglipron
Novo Nordisk
Ozempic
Verve Therapeutics
heterozygous familial hypercholesterolemia
Roche
lung cancer
tiragolumab
Vertex Pharmaceutical
VS-548
pain
JNJ
Bristol Myers Squibb
10 clinical trials to watch in the second half of 2023
BioPharma Dive
Wed, 06/28/23 - 11:44 am
FDA
clinical trials
Sarepta Therapeutics
Bridge Bio
Sanofi
Merck KGaA
Pfizer
Novo Nordisk
Verve Therapeutics
Roche
Vertex Pharmaceuticals
JNJ
Bristol Myers Squibb
ATTR-CM
Elevidys
tolebrutinib
evobrutinib
danuglipron
tiragolumab
VX-548
lazertinib
BridgeBio keeps FDA approval spree rolling, this time with nod for targeted bile duct cancer med
Fierce Pharma
Tue, 06/1/21 - 12:07 pm
Bridge Bio
FDA
Truseltiq
infigratinib
bile duct cancer
Neil Kumar's BridgeBio finds 7 new academic partners to join the fight against genetic disease
Endpoints
Tue, 04/13/21 - 10:20 am
Bridge Bio
genetic diseases
BridgeBio's Navire preps SHP2 blocker for lung cancer trial after positive mouse study
Fierce Biotech
Mon, 09/14/20 - 10:14 am
Bridge Bio
Navire Pharma
lung cancer
clinical trials
IACS-13909